The effectiveness of single ultrasound-guided high-intensity focused ultrasound (USgHIFU) ablation in managing placenta accreta spectrum (PAS) disorder
- PMID: 36525091
- DOI: 10.1007/s00404-022-06840-6
The effectiveness of single ultrasound-guided high-intensity focused ultrasound (USgHIFU) ablation in managing placenta accreta spectrum (PAS) disorder
Abstract
Objective: To evaluate the feasibility and effectiveness of single ultrasound-guided high-intensity focused ultrasound (USgHIFU) ablation in managing placenta accreta spectrum (PAS) disorder.
Materials and methods: We retrospectively analyzed 40 PAS patients between April 2017 and October 2021. All the patients received one session of HIFU treatment. Regular follow-up was done after HIFU treatment until normal menstruation returned and placental tissue disappeared. The patient's reproductive-related outcomes were obtained through telephone interviews.
Results: The median follow-up time for the 40 patients was 30.50 (15.75-44.00) months and the mean placental tissue elimination time was 45.29 ± 33.32 days. The mean duration of bloody lochia was 13.43 ± 10.01 days, with no incidences of severe bleeding. Notably, Linear regression analysis showed that the residual placenta volume before HIFU was a factor affecting the duration of bloody lochia after HIFU (R2 = 0.284, B = 0.062, P = 0.000). The normal menstrual return time was 58.71 ± 31.14 days. One (2.50%) patient developed an infection. Two (5.00%) patients were subjected to ultrasound-guided suction curettage for persistent vaginal discharge for more than one month without infection. Notably, 7 of the 18 patients who expressed reproductive plans became pregnant during the 4 to 53 months of follow-up without placental abnormalities. The remaining 11 patients were on contraceptives.
Conclusions: Single HIFU is an effective treatment option for managing PAS. However, future studies on further treatment strategies to reduce complications and promote patient recovery after HIFU ablation are desirable.
Keywords: High-intensity focused ultrasound; Placenta accrete; Placenta increta; Placenta percreta.
© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Comment in
-
Aortic balloon occlusion for placenta accreta spectrum: the higher, the better?Arch Gynecol Obstet. 2023 May;307(5):1657-1658. doi: 10.1007/s00404-022-06681-3. Epub 2022 Jul 11. Arch Gynecol Obstet. 2023. PMID: 35816206 No abstract available.
References
-
- Cheong JY, Kong TW, Son JH et al (2014) Outcome of pelvic arterial embolizafion for postpartum hemorrhage: A retrospective review of 117 cases[J ]. Obstet Gynecol Sci 57(1):17–27. https://doi.org/10.5468/ogs.2014.57.1.17 - DOI - PubMed - PMC
-
- Gu Y, Zhou Y, Li L, Li H, Wang S, Wang Y, Zuo C (2022) Cook Cervical Ripening Balloon for placenta accreta spectrum disorders with placenta previa: a novel approach to uterus preserving. Arch Gynecol Obstet. https://doi.org/10.1007/s00404-022-06476-6 - DOI - PubMed
-
- Youssefzadeh AC, Matsuzaki S, Mandelbaum RS, Sangara RN, Bainvoll L, Matsushima K, Ouzounian JG, Matsuo K (2022) Trends, characteristics, and outcomes of conservative management for placenta percreta. Arch Gynecol Obstet 306(3):913–920. https://doi.org/10.1007/s00404-021-06384-1 - DOI - PubMed
-
- Sentilhes L, Kayem G, Chandraharan E, Palacios-Jaraquemada J, Jauniaux E (2018) FIGO Placenta Accreta Diagnosis and Management Expert Consensus Panel. FIGO consensus guidelines on placenta accreta spectrum disorders: Conservative management. Int J Gynaecol Obstet. 140(3):291–298. https://doi.org/10.1002/ijgo.12410 - DOI - PubMed
-
- Lin K, Qin J, Xu K, Hu W, Lin J (2015) Methotrexate management for placenta accreta: a prospective study. Arch Gynecol Obstet 291(6):1259–1264. https://doi.org/10.1007/s00404-014-3573-1 - DOI - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Miscellaneous
